Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene and estradiol for vasomotor symptoms in postmenopausal women
NCT00332553Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in vasomotor symptoms comparing Raloxifene with Raloxifene + Estradiol (2 arms). Primary endpoint: Number of vasomotor symptoms at 12 weeks. Started Feb 2002; status: completed.
02
Drugs
raloxifeneestradiol
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT00332553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332553.